logo
Salud por Derecho
Eng
  • Esp
  • Eng
logo
  • ABOUT US
  • WHAT WE DO
  • COLLABORATE
  • NEWS
Imagen destacada
Home Slider
Before COVID-19, there was very little clinical research in infectious diseases in Spain
25/06/2020 by Salud in Home Slider

Viral diseases, such as COVID-19, were among those that received less attention before the start of the pandemic. This was found by the report Clinical research in Spain: A profile of clinical trials in the Spanish registry that the Salud por Derecho foundation published today. This document, which analyses data in the Spanish Clinical Studies Registry—from its creation in 2013 till September 2019—, reveals that around 35% of the clinical trials conducted in Spain are focused on studying cancer. This is followed by diseases of the nervous system, around 8%, immune system disorders, around 6%, cardiovascular diseases, around 5%, and viral diseases, around 4%.

Other equally important areas are found below these percentages, such as research for new antibiotics for the treatment of bacterial infections. Nevertheless, this area hardly receives any attention and represents, together with fungal diseases, a small 2% of the clinical studies’ total. These data, as noted in the report, demonstrate how necessary it is to rebalance the research agenda and revise its priorities to ensure that advances are made for all diseases, not only those that generate more economic benefit.

To date, 79% of clinical trials in Spain are led by pharmaceutical companies; 15% are conducted by universities, foundations, or research centers; and 6% have mixed funding, with both public and private investment. Therefore, the report recommends an increase in the resources earmarked to promote independent clinical trials led by public institutions, without the commercial interests of the pharmaceutical industry.

Transparency

Clinical trials are an essential stage in the development of therapies and medicines. They guarantee that the drugs are safe, effective, and, in many cases, allow us to know the added value compared with those already existing in the market. Moreover, they assist healthcare personnel to select the treatments to use for their patients, and serve as a basis for the Administration to decide which medicines to authorize, what price to set, and —in the case of Spain— if they will be funded by the public health system. Ultimately, clinical trials help to better understand diseases, their possible treatments, and their side effects.

However, the report presented today reveals a glaring lack of transparency in this area, as a quarter of completed studies have not published their results.

The analysis of the Spanish Clinical Studies Registry also shows a lack of essential information,  such as the completion date. In 70% of the completed trials, no completion date at the global level was provided, which prevents being able to determine if they comply with transparency regulations. The same occurred with data regarding the number of persons that participate in clinical trials in Spain and the active ingredient that is being investigated in each. In terms of the latter, the analysis highlights that this data was missing in 20% of cases.

The task of monitoring and surveillance of the publication of this information falls on the Spanish Agency of Medicines and Medical Devices, which the report asks to establish control mechanisms that ensure the publication of these data and establish a sanction policy for those cases in which the clinical trials do not comply with the regulations.

Beyond the analysis of the Spanish Clinical Studies Registry, the study proposes recommendations for transparency that would allow knowing relevant information such as costs and the economic terms of the agreements that are established with the hospitals that conduct the trials. Along these lines, keep in mind that the contribution made in our public hospitals via direct funding should be made known, as well as the hours of work of healthcare personnel, services or infrastructures, an investment that to date is not quantified, despite dealing with public resources.

Likewise, the report proposes that Spain commits itself and takes the appropriate measures to apply the resolution of the General Assembly of the World Health Organization last year —and signed by Spain—, in which they called on governments to improve transparency in clinical trials to facilitate the knowledge regarding costs, promote science, and provide the best therapies to patients.

The report is available at this link.

Compartir:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
Linkedin
Share on email
Email
Share on whatsapp
Whatsapp
Salud

Search

Subscribe to Newsletter

Estoy de acuerdo con la Política de privacidad.

LOCATION

Salud por Derecho
Duque Fernán Núñez, 2.
28012 Madrid
saludporderecho@saludporderecho.org

facebook twitter youtube

ABOUT US

About us

What we do

Collaborate

News

Privacy Policy

Cookie Policy

Publications

Press Area

SUBSCRIBE TO OUR NEWSLETTER

Estoy de acuerdo con la Política de privacidad.

Compartir:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
Linkedin
Share on email
Email
Share on whatsapp
Whatsapp
logo
Política de Cookies
Esta web utiliza cookies propias y de terceros para analizar tu navegación y ofrecerte un servicio más personalizado acorde a tus intereses. Continuar navegando implica la aceptación de nuestra Política de Cookies. También hemos actualizado nuestra Política de Privacidad para adecuarnos a la nueva normativa europea, puedes consultarla en la web. Aceptar Rechazar
Política de Cookies

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT